evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

45 questions · 45 findings · 20 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4 · 8.9%GRADE not reported 3 · 6.7%Very low 35 · 77.8%Low 1 · 2.2%Moderate 1 · 2.2%High 1 · 2.2%

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).

1 finding from 1 review

Maintenance treatment with antipsychotic drugs vs placebo/no treatment

Acceptability of treatment ‐ leaving the study early · schizophrenia

Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).

1 finding from 1 review

Buspirone vs placebo

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Ginkgo biloba vs placebo

Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Levetiracetam vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Vitamin E vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

BENZODIAZEPINES AS SOLE TREATMENT vs placebo

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).

1 finding from 1 review

Benzodiazepines vs antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Benzodiazepines vs placebo

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).

1 finding from 1 review

ECT plus standard care vs usual care

Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether ECT plus standard care changes satisfaction and acceptability of treatment (medium term) ‐ leaving… compared with standard care (very low certainty).

1 finding from 1 review

CLOZAPINE + AMISULPIRIDE vs CLOZAPINE + QUETIAPINE (Genc 2007)

Leaving the study early · people with treatment‐resistant schizophrenia

It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).

1 finding from 1 review